



Global Fund welcomes renewed commitment from GSK and ViiV Healthcare to expand community-led health solutions with £6 million joint pledge ahead of 8th Replenishment

21:30 GMT, 20 October 2025

LONDON/GENEVA – The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) today welcomed a new £6 million investment by GSK plc (LSE/NYSE: GSK) and ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, to strengthen community-led responses to HIV, tuberculosis (TB) and malaria in lower income countries. The commitment will be matched by the Gates Foundation, bringing this total investment in the Global Fund to £12 million.

Deborah Waterhouse, CEO, ViiV Healthcare and President, Global Health GSK said:

“We are proud to deepen our partnership with the Global Fund through this catalytic investment, which will help accelerate community-led responses to high burden infectious diseases such as HIV, tuberculosis, and malaria. We believe that sustainable health impact begins with empowering communities and the local organisations that know them best. By supporting programmes that are led by countries, community-owned and community-driven, we’re helping to build stronger, more resilient health systems where they’re needed most.”

The Rt Hon Yvette Cooper MP, Foreign Secretary for the United Kingdom, said: “The Global Fund has saved 70 million people from AIDS, TB and malaria since 2002. But the fight isn’t over. Climate change is contributing to a rise in malaria cases, HIV stigma still stops people from seeking treatment, and TB kills more people than any other infectious disease.

“As the UK co-hosts the Global Fund’s 8th replenishment with South Africa, it’s really welcome and important to see British business stepping up. Private sector investment and innovation is key to finding new treatments, improving access to care and ultimately ending AIDS, TB and malaria - because we know that global challenges won’t be solved if we wait until they land on our own doorstep.”

The announcement was made at a high-level event in London, marking a key milestone on the road to the 8th Replenishment Pledging Summit in November. The event showcased the power of partnership and solidarity to end AIDS, TB and malaria, building on recent momentum, catalyzing further commitments, and positioning the campaign for a successful pledging summit.

The Global Fund’s 8th Replenishment, which will finance programmes for the 2027–2029 grant cycle, is being co-hosted by the Republic of South Africa and the United Kingdom. With just five weeks to go until the Replenishment Summit, the Global Fund has raised over US\$3billion, including more than US\$1 billion from private sector donors - a significant portion of which has come from British philanthropy.

Hon. Ronald Lamola, Minister of International Relations and Cooperation of the Republic of South Africa, said, “South Africa is proud to co-host the Global Fund’s 8th Replenishment, and we welcome the renewed commitment from GSK and ViiV Healthcare to innovation and equity in global health. Partnerships like these — between governments, the private sector, and communities — are essential to sustain progress against HIV and

malaria. As we look toward the pledging summit, South Africa calls on all partners to match this spirit of solidarity and ambition, so that together we can build a healthier, more resilient world for all.”

GSK and ViiV Healthcare have long led innovation in the fight against HIV, malaria and TB, developing solutions that have helped to reduce the burden on communities most affected by highly prevalent infectious diseases. Their advances include a portfolio of medicines and vaccines which are used in the global setting for the treatment and prevention of diseases such as malaria and HIV, and a pipeline which includes research programmes for a next generation malaria vaccine and HIV medicines, and a vaccine candidate for TB – being developed in partnership with Gates MRI, Gates Foundation and Wellcome, all aimed at helping to accelerate the progress toward ending these diseases.

“The Global Fund continues to demonstrate how partnership can drive innovation and deliver impact where it’s needed most,” said **Joe Cerrell, Managing Director, Europe, the Middle East and East Asia of the Gates Foundation**. “As part of our ongoing commitment, we’re announcing up to \$100 million in matching funds to unlock greater private and philanthropic investment. We’re proud that the first contribution - £6 million from GSK and ViiV Healthcare - will activate this matching support. This collaboration underscores the Global Fund’s unique ability to turn bold ideas into real-world results, and we hope it will inspire others to join us in accelerating progress against HIV, TB, and malaria.”

Through this new investment with the Global Fund, GSK and ViiV Healthcare are continuing to go beyond scientific innovation, to help improve health outcomes for communities in lower income countries. The funding will support locally led partners and programmes accelerating progress in some of the world’s most affected regions. This commitment reinforces the vital role of grassroots leadership in shaping sustainable health solutions and comes at a pivotal time in the global health response, when catalytic funding for community-owned and community-led change is more important than ever.

“This commitment from GSK and ViiV Healthcare sends a powerful message - when public and private actors unite around a shared vision, we can drive real, lasting change,” said **Peter Sands, Executive Director of the Global Fund**. “We deeply appreciate their generosity and leadership at this critical moment. The innovation of the private sector is central to our partnerships progress, and the renewed pledge will continue our work to ensure those most impacted by infectious diseases, including women and girls, can access the best care when they need it.”

Catalytic funds, such as the one supported through this new pledge, are designed to tackle high-impact, high-priority initiatives that complement country allocations - driving innovation and accelerating progress in areas where it is most needed, for underserved communities.

Early and ambitious private sector commitments like this one are instrumental in building momentum, strengthening confidence in collective action, and inspiring others to contribute to the global effort to end HIV, TB, and malaria.

-ENDS-

About the Global Fund to Fight AIDS, Tuberculosis and Malaria

The Global Fund is a worldwide partnership to defeat HIV, TB and malaria and ensure a healthier, safer, more equitable future for all. We raise and invest up to US\$5 billion a year to fight the deadliest infectious diseases, challenge the injustice that fuels them, and strengthen health systems and pandemic preparedness in more than 100 of the hardest hit countries. We unite world leaders, communities, civil society, health workers and the private sector to find solutions that have the most impact, and we take them to scale worldwide. Since 2002, the Global Fund partnership has saved 70 million lives.

For more information, please visit: www.theglobalfund.org
Follow the Global Fund on X: <http://twitter.com/globalfund>
Join the Global Fund on Facebook: <http://www.facebook.com/theglobalfund>

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. Shionogi became a ViiV shareholder in October 2012. The company's aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com.

GSK enquiries

Media:

Simon Moore	+44 (0) 20 8047 5502	(London)
Kathleen Quinn	+1 202 603 5003	(Washington DC)
Alison Hunt	+1 540 742 3391	(Washington DC)

Investor Relations:	Constantin Fest	+44 (0) 7831 826525	(London)
	James Dodwell	+44 (0) 20 8047 2406	(London)
	Mick Readey	+44 (0) 7990 339653	(London)
	Steph Mountifield	+44 (0) 7796 707505	(London)
	Jeff McLaughlin	+1 215 751 7002	(Philadelphia)
	Frannie DeFranco	+1 215 751 3126	(Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q2 Results for 2025.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street
London
WC1A 1DG